Education
About Us
Working with TipRanks
Follow Us
Allarity Therapeutics, Inc. (ALLR)
NASDAQ:ALLR
RESEARCH TOOLSreports
ALLR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.61 - $20.43
Previous CloseN/A
Volume542.33K
Average Volume (3M)1.05M
Market Cap
$16.06M
Enterprise ValueN/A
Total Cash (Recent Filing)$18.46M
Total Debt (Recent Filing)$1.34M
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Nov 12, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding15,079,572
10 Day Avg. Volume628,420
30 Day Avg. Volume1,049,435
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.12
Price to Sales (P/S)0.00
P/FCF Ratio-0.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Allarity Therapeutics News
PremiumCompany Announcements
Allarity Therapeutics CEO to Present at Pharma Summit
PremiumCompany Announcements
Allarity Therapeutics Restructures Board of Directors
Options Prices
Currently, No data available
---
Ownership Overview
4.94% Insiders
0.07%
Mutual Funds
0.13% Other Institutional Investors
94.86% Public Companies and Individual Investors
ALLR FAQ
What was Allarity Therapeutics, Inc.’s price range in the past 12 months?
Allarity Therapeutics, Inc. lowest stock price was $0.61 and its highest was $20.43 in the past 12 months.
What is Allarity Therapeutics, Inc.’s market cap?
Allarity Therapeutics, Inc.’s market cap is $16.06M.
When is Allarity Therapeutics, Inc.’s upcoming earnings report date?
Allarity Therapeutics, Inc.’s upcoming earnings report date is Nov 12, 2025 which is in 172 days.
How were Allarity Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is Allarity Therapeutics, Inc. overvalued?
According to Wall Street analysts Allarity Therapeutics, Inc.’s price is currently Overvalued.
Does Allarity Therapeutics, Inc. pay dividends?
Allarity Therapeutics, Inc. does not currently pay dividends.
What is Allarity Therapeutics, Inc.’s EPS estimate?
Allarity Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Allarity Therapeutics, Inc. have?
Allarity Therapeutics, Inc. has 15,079,572 shares outstanding.
What happened to Allarity Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Allarity Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ALLR
Company Description
Allarity Therapeutics, Inc.
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.